Can Ampio Pharmaceuticals and Arena Pharmaceuticals Regain Investor’s Confidence?
New York, NY – GDP INSIDER – 10/03/2014.
This article discusses two struggling pharmaceutical companies: Ampio Pharmaceuticals Inc(NYSEMKT:AMPE) and Arena Pharmaceuticals, Inc.(NASDAQ:ARNA)
When a trial-stage biopharmaceutical company like Ampio Phamaceuticals Inc(NYSEMKT:AMPE) invests time and energy into the creation of a new product, there is always a chance that their efforts will not prove to be fruitful. However, for the company’s phase III study of Ampion to not demonstrate efficacy in the treatment of knee arthritis can best be described as disappointing. The results of the study have led to the company’s recent free fall.
Moving forward, the Colorado-based company may want to consider pursuing alternative products. The company currently has a bid price of $3.85 x 500 and an offer price of $4.14 x 300, indicating the stock is highly liquid.
Like Ampio Pharmaceuticals, Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) has also fallen on hard times. The biotechnology company has fallen $1.77 since closing at a price of $5.84 on July 3rd, 2014. Moreover, the company did not see its value rise after its APD811 product had received orphan drug status from the FDA. Although the company plans to proceed with its phase II study of the drug later this year, the company may not see its value rebound until its current line of products begins to produce.
The California-based company develops drugs that target G protein-coupled receptors like BELVIQ, which is used to treat chronic weight management in adults. However, the product’s sales figures have failed to impress investors and the stock’s value continues to fall.
HotStockGains.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word BREAKOUT to 555888 from your cell phone.
Additionally, HotStockGains free newsletter provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.
Disclosure: HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://hotstockgains.com/disclaimer/ for complete risks and disclosures.